At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 180 enrolled
Drug / intervention
Unfractionated heparindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Optimal Target of Activated Clotting Time During Percutaneous Coronary Intervention and Outcomes: The Randomized OPTIMAL-ACT Trial
In Brief
A Phase 2 clinical trial evaluating Unfractionated heparin for Coronary Artery Disease and 3 related conditions. Completed, enrolled 180 participants across 1 site.
Detailed Summary
The purpose of this study is to find the ideal range of the activated clotting time (ACT) during percutaneous coronary intervention (PCI) that is associated with lowering the rate of undesirable medical outcomes
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease, Ischemic Heart Disease, Anticoagulant-induced Bleeding, Coronary Syndrome
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedDec 2018
Enrollment StartFeb 2019
Primary CompletionOct 2021
TodayJul 2026
First PostedDec 11, 2018
Enrollment StartFeb 8, 2019
Primary CompletionOct 25, 2021
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 7.6 years ago
Interventions
Unfractionated heparindrug
Administration of unfractionated heparin will be assessed using the activated clotting time